Byotrol Plc
("Byotrol" or the
"Company")
Trading
Update
Proposed Cancellation of
admission of Ordinary Shares to trading on AIM
Proposed Re-registration as a
Private Limited Company
Proposed Post-Cancellation
Fundraising
Byotrol Plc (AIM: BYOT), the
specialist infection prevention and control company, today provides
a year end trading update.
Alongside this, the Company
announces the proposed cancellation of the admission of its
ordinary shares to trading on AIM (the "Cancellation"),
re-registration of the Company as a private limited company (the
"Re-registration") and a proposal to undertake a post-Cancellation
fundraising as an unquoted company.
Further details are set out below in
this announcement.
A circular ("Circular") will be sent
to Shareholders later today, setting out the background to and
reasons for the proposed Cancellation and the Re-registration, as
well as details of the shareholder authorities required to enable a
fundraising proposed to take place following the Re-registration,
including a proposed share split ("Capital Reorganisation") and new
articles of association. The Circular will also contain a notice
convening a general meeting ("General Meeting"), at which
Shareholders are invited to consider the proposed resolutions
therein.
Year End Trading Update
The Company expects to report
results for the full year to 31 March 2024 as follows:
Product sales
·
Product sales are likely to be in line with
expectations at approximately £3.9m, showing modest growth on £3.7m
in the previous year on a like-for-like basis (excluding
discontinued items). Including discontinued items,
prior year product sales were £4.3m.
·
The product sales business is now showing very
encouraging momentum, benefitting from its primary focus on animal
healthcare and niche human health (non-medical devices). In
the year to 31 March 2024, 68% of product sales were in animal
health, compared to 63% in the comparative period on a
like-for-like basis. Gross margin is tracking to 43.0%
for the year, which demonstrates a good return for a 100%
outsourced manufacturing model, compared to 42.6% in the prior
year.
Intellectual Property
·
We are not expecting any further IP revenue in the
year to 31 March 2024. As previously disclosed, we have
concentrated this year on maximising cash from IP and are pleased
to report we have already generated cash from IP of approximately
£800k this year (£400k in the previous year). This includes
an increase in cash receipts compared to plan, from early
termination of two existing licenses (with Turtle Wax Europe Ltd
and Tristel Plc). Both sets of assets were deemed non-core to the
counterparties' respective strategies and in both cases we agreed
to terminate by mutual consent. We then agreed to sell to
Tristel the underlying IP relating to one of the three
previously licensed formulations, the proceeds of which are
included in the 'cash-generated' figure above. These two
transactions are positive in cash terms but will also result in an
exceptional accounting charge to our P&L at year end of £550k,
reflecting a write-off of future minimum guaranteed
royalties.
·
Our two major IP initiatives - Syensqo (previously
Solvay) Actizone and Integrated Resources Inc's Byotrol 24 - remain
as previously reported, with continued progress towards launches
via their own respective clients, but not sufficient commercial
traction yet to be material to the Company and with no reliable
visibility of when that will change. Additional returns from
these relationships remain unpredictable in timing and
magnitude.
With no further IP revenue expected
before the financial year end, the Company now expects headline
EBITDA before exceptionals of approximately -£1.0m, compared to
-£0.7m the previous year.
As previously reported, our cash
position remains tight and access to further capital is challenging
in current market circumstances. At present we have
sufficient cash to finance current operations and commitments, but
we will require a restructure and a small fundraise (as detailed
below) to ensure that continues to be the case, absent an injection
from IP transactions or strategic investment.
Background to the Proposed Cancellation
As part of the required restructure,
and after careful consideration and consultation with key
stakeholders, the Directors have concluded unanimously that being
listed is no longer in the best interests of the Company and that
we should now seek cancellation of the Company's ordinary shares on
AIM. The Directors believe - despite recent good progress in
the products business - that it is no longer financially viable for
Byotrol to continue to trade as an AIM quoted business.
In reaching this conclusion the
Board has considered the following key factors (amongst
others):
·
Our urgent need to reach sustainable break-even
and to eliminate all non-core costs to help us achieve that.
A continued AIM quotation has become unnecessarily costly and
regulatorily burdensome for our current stage of
development.
·
The lack of liquidity in our ordinary shares and
the volatility of our share price as a result, which in turn has a
materially adverse impact on the perception of the Company by
customers, suppliers, employees and other stakeholders. The
Directors do not believe the current market valuation reflects the
underlying strength of the Company's product business, its IP
portfolio or the current market opportunity.
·
The impact of the regulatory regime on strategic
flexibility. The Board believes that an unlisted company can take
and implement decisions more quickly than a company that is
publicly traded.
Therefore, as a result of this
review, the Board has unanimously concluded that the proposed
Cancellation and Re-registration is in the best interests of the
Company and its Shareholders as a whole.
Process for Cancellation
Under the AIM Rules, it is a
requirement that the Cancellation must be approved by Shareholders
holding not less than 75 per cent. of votes cast by Shareholders at
the General Meeting. Accordingly, the notice of General Meeting set
out in the Circular contains a special resolution to approve the
Cancellation (the "Cancellation Resolution").
Furthermore, Rule 41 of the AIM
Rules requires any AIM company that wishes the London Stock
Exchange to cancel the admission of its shares to trading on AIM to
notify shareholders and to separately inform the London Stock
Exchange of its preferred cancellation date at least 20 clear
business days prior to such date. In addition, a period of at least
five clear business days following Shareholders' approval of the
Cancellation is required before the Cancellation may become
effective.
In accordance with AIM Rule 41, the
Directors have notified the London Stock Exchange of the Company's
intention, subject to the Cancellation Resolution being passed at
the General Meeting on 22 April 2024, to cancel the Company's
admission of the Ordinary Shares to trading on AIM. Accordingly, if
the Cancellation Resolution is passed by the Shareholders, the
Cancellation will become effective at 7.00 a.m. on 30 April
2024.
Process for Re-registration
Following the Cancellation, the
Directors believe that the requirements and associated costs of the
Company maintaining its public company status will be difficult to
justify and that the Company will benefit from the more flexible
requirements and lower costs associated with private limited
company status. It is therefore proposed to re-register the Company
as a private limited company. In connection with the
Re-registration, it is proposed that new articles of association
(the "New Articles") be adopted to reflect the change in the
Company's status to a private limited company. The principal
effects of the Re-registration and the adoption of the New Articles
on the rights and obligations of Shareholders and the Company will
be summarised in the Circular. Under the Companies Act 2006, the
Re-registration and the adoption of the New Articles must be
approved by Shareholders holding not less than 75 per cent. of
votes cast by Shareholders at the General Meeting (the
"Re-registration Resolution").
If the Cancellation Resolution and
the Re-registration Resolution are approved at the General Meeting,
an application will be made to the Registrar of Companies for the
Company to be re-registered as a private limited company.
Re-registration will take effect when the Registrar of Companies
issues a certificate of incorporation on Re-registration. The
Registrar of Companies will issue the certificate of incorporation
on Re-registration when it is satisfied that no valid application
can be made to cancel the Re-registration Resolution or that any
such application to cancel the Re-registration Resolution has been
determined and confirmed by the Court.
Capital Reorganisation
As the Company is not permitted by
law to issue shares at an issue price which is below their nominal
value, the Company's ability to raise funds from investors is
currently limited due to the proximity of the mid-market price of
the shares to their nominal value. Whilst the Board's objective is
to achieve the highest possible issue price for the Company when
issuing shares, it is cognisant that, given current market
conditions, the Company may be unable to issue shares at a
sufficient discount to their market price in order to attract
further equity investment into the business.
In order to enable the Company to
issue shares at an issue price which exceeds their nominal value,
shareholder approval is being sought to complete a Capital
Reorganisation.
The Capital Reorganisation will
involve:
·
each of the existing ordinary shares of 0.25p each
("Existing Ordinary Shares") will be subdivided into and
reclassified as one New Ordinary Share (defined below) and one
Deferred Share (defined below);
·
each New Ordinary Share will be an ordinary share
in the capital of the Company with a nominal value of £0.0001 (0.01
pence) ("New Ordinary Share"); and
·
each Deferred Share will be a deferred share in
the capital of the Company with a nominal value of £0.0024 (0.24
pence) ("Deferred Share").
Subject to the passing of the
relevant resolutions at the GM, the Capital Reorganisation will
take effect at the close of business on the date of the GM ("Record
Date").
As a consequence of, and immediately
following, the Capital Reorganisation becoming effective each
Shareholder's holding of New Ordinary Shares will be the same as
the number of Existing Ordinary Shares held by them on the Record
Date. Each shareholder's proportionate interest in the Company's
issued ordinary share capital will, and thus the aggregate value of
their holding should, remain unchanged as a result of the Capital
Reorganisation.
The New Ordinary Shares will have
the same rights as those currently accruing to the Existing
Ordinary Shares in issue under the articles of association of the
Company, including those relating to voting and entitlement to
dividends.
The Deferred Shares created will be
effectively valueless as they will not carry any rights to vote or
dividend rights. The Deferred Shares will not be traded on the AIM
Market and will not be transferable without the prior written
consent of the Board. No share certificates will be issued in
respect of the Deferred Shares, nor will CREST accounts of
Shareholders be credited in respect of any entitlement to Deferred
Shares.
The intention is that Deferred
Shares will be cancelled in due course following a court approved
reduction of capital or other means, if available.
Directorate Changes
The current executive management
team will remain in place after the proposed Cancellation and
Re-registration process.
Should Cancellation be approved by
Shareholders, Dr Trevor Francis, Non-Executive Chairman since April
2023, will step down and return to a Non-Executive Directorship. Dr
Francis will be replaced by Ashley Head, currently Non-Executive
Director.
Secondary Market Trading Facility
The Directors are aware that should
the proposed Cancellation be approved by Shareholders at the
General Meeting, it will become more difficult to buy and sell
shares in the Company. Therefore, post de-listing, the Company
intends to implement a Matched Bargain Facility with Asset Match to
assist Shareholders with conducting future share
transactions.
There can be no guarantee when this
facility will be made available to Shareholders or kept in place
indefinitely.
Takeover Code
The Takeover Code applies to all
offers for companies which have their registered offices in the
United Kingdom, the Channel Islands or the Isle of Man if any of
their equity share capital or other transferable securities
carrying voting rights are admitted to trading on a UK regulated
market or a UK multilateral trading facility or on any stock
exchange in the Channel Islands or the Isle of Man.
The Takeover Code also applies to
all offers for companies (both public and private) which have their
registered offices in the United Kingdom, the Channel Islands or
the Isle of Man and which are considered by the Takeover Panel to
have their place of central management and control in the United
Kingdom, the Channel Islands or the Isle of Man, but in relation to
private companies only if one of a number of conditions is met -
for example, if the company's shares were admitted to trading on a
UK regulated market or a UK multilateral trading facility or on any
stock exchange in the Channel Islands or the Isle of Man at any
time in the preceding ten years.
In view of the Re-registration, and
provided that the Company's place of central management and control
continues to be considered by the Takeover Panel to be in the
United Kingdom, the Takeover Code will apply to the Company for ten
years following the Cancellation, including the requirement for a
mandatory cash offer to be made if either:
·
a person acquires an interest in shares which,
when taken together with the shares in which persons acting in
concert with it are interested, increases the percentage of shares
carrying voting rights in which it is interested to 30 per cent. or
more; or
·
a person, together with persons acting in concert
with it, is interested in shares which in the aggregate carry not
less than 30 per cent. of the voting rights of a company but does
not hold shares carrying more than 50 per cent. of such voting
rights and such person, or any person acting in concert with it,
acquires an interest in any other shares which increases the
percentage of shares carrying voting rights in which it is
interested.
Under Rule 9 of the Takeover Code,
when any person or group of persons acting in concert, individually
or collectively, are interested in shares which in aggregate carry
not less than 30 per cent. of the voting rights of a company but do
not hold shares carrying more than 50 per cent. of the voting
rights of a company and such person or any person acting in concert
with him/her acquires an interest in any other shares, which
increases the percentage of the shares carrying voting rights in
which he/she is interested, then that person or group of persons is
normally required by the Panel to make a general offer in cash to
all shareholders of that company at the highest price paid by them
for any interest in shares in that company during the previous 12
months. Rule 9 of the Takeover Code further provides that where any
person, together with persons acting in concert with him/her, holds
over 50 per cent. of the voting rights of a company to which the
Takeover Code applies and acquires additional shares which carry
voting rights, then that person will not generally be required to
make a general offer to the other shareholders to acquire the
balance of the shares not held by that person or his/her concert
parties.
Following the expiry of the 10 year
period from the date of the Cancellation (subject to the
Re-registration occurring), or such other date on which the
Takeover Code ceases to apply to the Company, the Company will no
longer be subject to the provisions of the Takeover Code. A summary
of the protections afforded to Shareholders by the Takeover Code
which will be lost is set out in the Circular.
Fundraising
As previously reported, the
Company's cash position remains tight and access to further capital
is challenging in current market circumstances. At present, whilst
we have sufficient cash to finance current operations and
commitments, the proposed fundraising will ensure that continues to
be the case, absent an injection from IP transactions or strategic
investment.
Accordingly and following the
Cancellation, Re-registration and Capital Reorganisation, the
Company intends to effect an equity fundraising to raise up to
£500,000 by way of an issue of new Ordinary Shares at a price to be
agreed. The Directors intend to take up at least their share
of the fund raising on a prorated basis to current equity
holdings.
General Meeting
The Company is convening the General
Meeting to consider and, if thought fit, pass: (i) an ordinary
resolution to approve the Capital Reorganisation (ii) a special
resolution to approve the Cancellation, (iii) a special resolution
to approve the Re-registration (including approving the New
Articles), (iv) an ordinary resolution for an authority to allot in
connection with the proposed fundraising, and (v) a special
resolution for authority to disapply pre-emption rights in
connection with the proposed fundraising. The resolution to approve
the Re-registration is conditional on the resolution approving the
Cancellation being passed by Shareholders at the General Meeting
and the Cancellation becoming effective.
Should the Cancellation be approved
by Shareholders at the General Meeting, the Group will implement a
matched bargain facility with a third party facility provider which
will facilitate Shareholders buying and selling Ordinary Shares on
a matched bargain basis following Cancellation.
The General Meeting will be held at
the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane,
London EC4R 3TT commencing at 11.00 a.m. on 22 April
2024.
Formal notice convening the General
Meeting and setting out the resolutions to be considered at it will
be set out in the Circular which is expected to be posted to
Shareholders today. In line with the Company's approach at annual
general meetings, hard copy proxy forms are not being sent to
Shareholders in connection with the General Meeting. The Company
would like to encourage Shareholders to vote electronically or
appoint a proxy electronically, which can be done via
www.signalshares.com, via the LinkVote+ app or, where Ordinary
Shares are held in CREST, via CREST. Certain Shareholders may also
be able to appoint a proxy electronically via the Proximity
platform. Shareholders may also request a hard copy form of
proxy directly from the Company's registrar, Link Group, by calling
0371 664 0300 or by emailing shareholderenquiries@linkgroup.co.uk.
Notwithstanding the method of
appointment, proxy appointments must be received by Link Group by
11.00 a.m. on 18 April 2024, being 48 hours before the time fixed
for the General Meeting.
A copy of the Circular, the notice
of General Meeting and the New Articles will be made available on
the Company's website at www.byotrol.com.
For
further information contact:
Byotrol Plc
|
|
Dr Trevor Francis, Non- Executive
Chairman
|
+44
(0)1925 742 000
|
David Traynor, Interim Chief
Executive Officer
Chris Sedwell, Chief Financial
Officer
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
+44 (0)20
7220 0500
|
Geoff Nash/George Dollemore -
Corporate Finance
Nigel Birks/Harriet Ward -
ECM
|
|
|
|
|
|
Flagstaff Strategic and Investor
Communications
|
+44 (0)20
7129 1474
|
Tim
Thompson/Andrea Seymour/Fergus Mellon
|
byotrol@flagstaffcomms.com
|
This announcement is released by Byotrol Plc and, prior to
publication, the information contained herein was deemed to
constitute inside information under the Market Abuse Regulations
(EU) No. 596/2014. Such information is disclosed in accordance with
the Company's obligations under Article 17 of
MAR.
Notes to
editors
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection
prevention and control company, operating globally in the animal
and human healthare, industrial, institutional and consumer
sectors, providing low toxicity products with a broad-based and
targeted efficacy across all microbial classes; bacteria, viruses
(including coronavirus), fungi, moulds, mycobacteria and
algae.
Byotrol's products can be used stand-alone or as ingredients
within existing products, where they can significantly improve
their performance, especially in personal hygiene, domestic and
industrial disinfection, odour control, food production and food
management.
Byotrol develops and commercialises technologies that create
easier, safer and cleaner lives for everyone.
For more information, go to byotrol.com
EXPECTED TIMETABLE OF PRINCIPAL
EVENTS (1) (2)
|
|
Notice provided to the London Stock
Exchange to notify it of the proposed Cancellation
|
28 March
2024
|
|
|
Publication and posting of this
document
|
28 March
2024
|
|
|
Latest time and date for receipt of
online proxy votes or completed Forms
of Proxy in respect of the General
Meeting
|
11.00 a.m.
on 18 April 2024
|
|
|
General Meeting
|
11.00 a.m.
on 22 April 2024
|
|
|
Record Date and final date and time
for trading in Existing Ordinary Shares(3)
|
6.00 p.m.
on 22 April 2024
|
|
|
Expected date of admission of the
New Ordinary Shares arising from the Capital
Reorganisation
|
23 April
2024
|
|
|
Expected last day of dealings in New
Ordinary Shares on AIM
|
29 April
2024
|
|
|
Expected date of
Cancellation(4)
|
7.00 a.m.
on 30 April 2024
|
|
|
Expected date of
Re-registration(5)
|
By 21 May
2024
|
|
|
Matched bargain facility for
Ordinary Shares commences
|
By 30
April 2024
|
Notes:
(1)
All of the times referred to in this announcement
refer to London time, unless otherwise stated.
(2)
Each of the times and dates in the above timetable is subject to change. If any of the
above times and/or dates change, the
revised times and dates will be notified to Shareholders
by an announcement through a Regulatory
Information Service and/or the Company's website.
(3)
The Capital Reorganisation and admission of the New
Ordinary Shares to trading on AIM requires the approval of not less
than 50% of the votes cast by Shareholders at the General
Meeting
(4)
The Cancellation requires the approval of not less
than 75% of the votes cast by Shareholders at the General
Meeting.
(5)
The Re-registration requires the approval of not
less than 75% of the votes cast by Shareholders at the General
Meeting.